All In Biotech

Drug Trial Radar · NCT07891169

Master Protocol for Basket Clinical Trials of Targeted Therapies Based on Proteome and Whole Exome Sequencing Screening in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

2,800

Planned (sponsor's estimate)

Start

Nov 18, 2024

Primary completion

Dec 31, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
National Cancer Center, KoreaGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
Oct 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Screening
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study Overview This study evaluates a proteogenomic screening platform to identify precise therapeutic targets for patients with advanced solid tumors. While traditional precision medicine relies on DNA sequencing (genomics), this research adds protein analysis (proteomics) to better understand how cancer cells function and respond to treatment. 1. Background and Purpose Standard genomic testing often fails to predict whether a patient will respond to a specific drug because DNA mutations do not always result in active protein expression. By integrating Whole Exome Sequencing (WES) with phosphoproteomics (the study of protein activation), this study aims to: * Identify active signaling networks that DNA testing alone might miss. * Evaluate the feasibility and cost-effectiveness of this integrated platform compared to traditional methods. * Help match patients to the most effective targeted therapies through a "Basket Trial" framework, where treatment is based on molecular signatures rather than where the cancer started in the body. 2. Target Population * Adults (19 years and older) with histologically confirmed metastatic or locally advanced solid tumors. * Patients with Stage III, IV, or those at a high risk of recurrence. * Participants must have a life expectancy of at least 3 months and a good performance status (ECOG 0-2). 3. Study Procedures * Specimen Collection: Researchers will collect tumor tissue through biopsy or surgery. To preserve the integrity of proteins, these samples must be snap-frozen (Fresh-Frozen) immediately after extraction. * Analysis: The study will analyze the tissue and blood samples to characterize the patient's unique proteogenomic profile. * Treatment Assignment: If a specific molecular variant is identified (such as HRD or ALK/ROS1/MET signatures), and a matching sub-protocol is available, the patient may be enrolled in a targeted therapy trial. Patients who do not meet these criteria will continue with the standard of care. 4. Expectations and Logistics This is a multicenter, prospective screening study involving a nationwide logistics system to ensure high-quality sample transport. The study aims to enroll a total of 2,800 subjects (approximately 560 per year) and is expected to continue through December 31, 2028. 5. Potential Benefits and Risks * Benefits: Participants may gain access to targeted therapies based on their cancer's specific molecular profile. * Risks: While the study does not add new invasive procedures beyond standard care, there are potential psychosocial risks related to genomic findings and the sharing of de-identified data for research purposes.

Conditions

  • Advanced Solid Tumors
  • Metastatic Solid Tumors
  • Locally Advanced Solid Tumors
  • Recurrent Solid Tumors
  • Proteogenomic Screening and Molecular Signaling
  • Basket Clinical Trial Framework
  • Targeted Therapy Based on HRD (Homologous Recombination Deficiency) and ALK/ROS1/MET Signatures

Interventions

  • Homologous Recombination Deficiency (HRD)Drug

    This arm consists of subjects identified with Homologous Recombination Deficiency (HRD)-positive proteogenomic signatures through the master screening protocol . These subjects are eligible for matching targeted therapy sub-protocols

  • ALK/ROS1/METDrug

    ALK/ROS1/MET-targeted therapy (Crizotinib 250mg )

  • standard care treatmentDrug

    This arm is for subjects who do not meet the specific molecular criteria for the available targeted sub-protocols following proteogenomic screening . These subjects will continue to receive the standard-of-care treatment at their respective institutions

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of Successful Identification of Actionable Therapeutic TargetsTime frame: From the date of pre-treatment tissue sample collection until the completion of proteogenomic analysis and report generation, assessed up to 3 weeks (21 days) per participant.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • National Cancer Center, Korea

    Goyang, Gyeonggido, South Korea

  • National Cancer Center, Korea

    Goyang-si, Gyeonggido, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.